Psilocybin and Pre-Existing Mental Health Diagnoses: A Condition-by-Condition Risk Table

A structured lookup table, not a prose article, mapping specific diagnoses (bipolar I and II, borderline personality, schizophrenia spectrum, OCD, PTSD, generalised anxiety) to what peer-reviewed evidence actually says about risk, contraindication level, and what screening questions matter.

You have a diagnosis on your chart, and a retreat form is asking whether you have any mental health conditions. Or you are deciding for yourself whether a trip is a reasonable thing to do given what you already live with. The honest answer depends heavily on which condition, and most blanket advice flattens that. Below is a condition-by-condition breakdown of what the peer-reviewed literature actually supports, how strong a red flag each one is, and the questions worth asking before you go any further.

A note on what this is not: this is not a clearance. A table cannot know your history, your medications, or how stable you are right now. The lowest-risk choice is always not to use at all. If you do, the information below is meant to help you weigh a decision you have already started making.

The high-caution conditions

These are where the evidence, and the caution in clinical trials, runs strongest.

Schizophrenia spectrum and other primary psychotic disorders

• Contraindication level: Strong / avoid. Psilocybin is a serotonergic psychedelic that can produce transient psychotic-like states in anyone. In someone with a psychotic disorder, the concern is precipitating or worsening a psychotic episode.
• Nearly every psilocybin trial excludes people with a personal history of psychotic disorders, which means there is almost no safety data in this group - the absence of data is itself a reason for caution, not reassurance.
• Screening questions: Have you ever been diagnosed with schizophrenia, schizoaffective disorder, or a psychotic disorder? Have you experienced hallucinations or delusions when not on a drug?

Bipolar I disorder

• Contraindication level: Strong / avoid in most cases. The specific documented concern is triggering mania, hypomania, or a mixed state. Case reports describe manic episodes following psychedelic use in people with bipolar disorder. This is the clearest signal in the bipolar literature.
• Bipolar I (defined by full manic episodes) carries more concern than bipolar II.
• Screening questions: Have you ever had a manic episode - days of greatly reduced need for sleep, racing thoughts, grandiosity, risky behavior? Is your mood currently stable, and for how long?

Family history of psychotic or bipolar illness

• Contraindication level: Caution. A first-degree relative with schizophrenia or bipolar I is treated as a relative contraindication in many research settings, on the theory of latent vulnerability. The evidence here is precautionary rather than strong.
• Screening question: Does a parent, sibling, or child have schizophrenia or bipolar I disorder?

The it-depends conditions

Here the picture is genuinely mixed, and individual stability matters more than the label.

Bipolar II disorder

• Contraindication level: Caution / individualized. Small surveys of people with bipolar disorder who used psychedelics report a mix of outcomes, including some who experienced new or worsening symptoms and some who reported benefit. This is self-reported, retrospective, low-quality evidence. The mania risk is thought to be lower than in bipolar I but is not zero.
• Screening questions: How are your episodes managed now? Have you had a hypomanic episode triggered by an antidepressant or other medication in the past?

Borderline personality disorder

• Contraindication level: Caution. BPD is often an exclusion criterion in trials, partly because the intensity and emotional flooding of a trip can be destabilizing, and partly because trial settings are not built to hold acute distress. Evidence specific to BPD is sparse.
• The relevant risks are emotional overwhelm during the experience and difficulty integrating it afterward, rather than a specific pharmacological danger.
• Screening questions: Do you have a current safety plan? Do you have reliable support to process a difficult experience in the days after?

The conditions under active study

These are where psilocybin is being researched as a potential treatment - which is not the same as being safe outside a trial.

Treatment-resistant and major depression

• Contraindication level: Lower, but context-dependent. This is the most-studied indication, with emerging-to-moderate evidence for benefit in controlled settings. Those settings include screening, preparation, a sitter, and integration - none of which are guaranteed at an unregulated retreat.
• Screening questions: Are you currently suicidal? What antidepressants are you taking, and have you discussed them with a prescriber? (Medication interactions are a separate question - see the medication interaction table.)

PTSD

• Contraindication level: Caution / emerging. Trauma-focused psychedelic research is active but earlier-stage for psilocybin specifically. A trip can surface traumatic material intensely and without warning, which can be therapeutic with support and harmful without it.
• Screening questions: Do you have grounding tools and a trusted person for afterward? Have you had flashbacks that left you unable to function?

OCD

• Contraindication level: Lower, emerging evidence. Small early studies have explored psilocybin for obsessive-compulsive symptoms with some promising signals. The evidence base is small.
• Screening question: Are your symptoms currently manageable enough that an unstructured, unpredictable experience would not tip you into crisis?

Generalized anxiety

• Contraindication level: Lower, but anxiety can spike during a trip. Acute anxiety and fear are common features of coming up, even in people without a diagnosis. For someone with GAD, set, setting, dose, and support make the difference between a hard passage and a panic spiral.
• Screening question: Do you have someone sober and calm present who can talk you down?

How to use this

No single row is a clearance. Two things cut across every condition: your current stability, and whether you have real support during and after. If you are taking any psychiatric medication, treat interactions as a separate, serious question. And if any part of you is reaching for a trip to escape a crisis rather than approach something from a stable base, that is the strongest signal of all to wait.

Browse all articles →